2 11, 2022 Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiency Neal Evan Caminsky2022-11-15T09:12:37-05:00November 2, 2022|Funded Research Results, Pillar 3|
4 10, 2022 Cytokines and lipid mediators of inflammation in lungs of SARS-CoV-2 infected mice Neal Evan Caminsky2022-11-15T09:14:07-05:00October 4, 2022|Funded Research Results, Pillar 3|
30 09, 2022 A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS -CoV-2 infection Neal Evan Caminsky2022-11-15T09:14:05-05:00September 30, 2022|Funded Research Results, Pillar 3|
27 09, 2022 Human coronaviruses disassemble processing bodies Neal Evan Caminsky2022-11-15T09:14:02-05:00September 27, 2022|Funded Research Results, Pillar 3|
26 09, 2022 Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants Neal Evan Caminsky2022-11-15T09:14:00-05:00September 26, 2022|Funded Research Results, Pillar 3|
